Analysts Jim Cramer recommends waiting for a pullback before buying Moderna (MRNA) shares as the company unveils a promising cancer pipeline
Moderna is gaining renewed investor interest as it expands its pipeline beyond Covid-19 vaccines, with promising developments in cancer therapies and other vaccine programs. This shift could signal a potential turnaround for the company after a period of uncertainty.